Eptacog alfa biosimilar (Valin Technologies)

依他凝血素α生物类似药 (Valin Technologies)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEptacog alfa biosimilar (Valin Technologies)

Drug Alias Name依他凝血素α生物仿制药 (Valin Technologies)重组凝血因子VIIa生物仿制药 (Valin Technologies)

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factorBiologics > Biosimilar

Mechanisms of ActionCoagulation factor IX stimulantsCoagulation factor X stimulantsBlood coagulation pathway activation +[4]

TargetsCoagulation factor IXCoagulation factor X

Therapy Area/IndicationsHemophilia A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesValin Technologies

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsHemophilia A

Inactive IndicationsN/A

ATC CodeN/A